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Alzheimer’s disease (AD), the most prevalent dementia in the elderly, is characterized
by progressive synaptic and neuronal loss. Mitochondrial dysfunctions have been
consistently reported as an early event in AD and appear before Aβ deposition
and memory decline. In order to define a new neuroprotectant strategy in AD
targeting mitochondrial alterations, we develop tetrahydro-N,N-dimethyl-2,2-diphenyl-3-
furanmethanamine (ANAVEX2-73, AE37), a mixed muscarinic receptor ligand and a
sigma-1 receptor (σ1R) agonist. We previously reported that ANAVEX2-73 shows anti-
amnesic and neuroprotective activities in mice injected intracerebroventricular (ICV)
with oligomeric amyloid-β25–35 peptide (Aβ25–35). The σ1R is present at mitochondria-
associated endoplasmic reticulum (ER) membranes, where it acts as a sensor/modulator
of ER stress responses and local Ca2+ exchanges with the mitochondria. We therefore
evaluated the effect of ANAVEX2-73 and PRE-084, a reference σ1R agonist, on
preservation of mitochondrial integrity in Aβ25–35-injected mice. In isolated mitochondria
from hippocampus preparations of Aβ25–35 injected animals, we measured respiration
rates, complex activities, lipid peroxidation, Bax/Bcl-2 ratios and cytochrome c release
into the cytosol. Five days after Aβ25–35 injection, mitochondrial respiration in mouse
hippocampus was altered. ANAVEX2-73 (0.01–1 mg/kg IP) restored normal respiration
and PRE-084 (0.5–1 mg/kg IP) increased respiration rates. Both compounds prevented
Aβ25–35-induced increases in lipid peroxidation levels, Bax/Bcl-2 ratio and cytochrome
c release into the cytosol, all indicators of increased toxicity. ANAVEX2-73 and
PRE-084 efficiently prevented the mitochondrial respiratory dysfunction and resulting
oxidative stress and apoptosis. The σ1R, targeted selectively or non-selectively,
therefore appears as a valuable target for protection against mitochondrial damages
in AD.
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INTRODUCTION
Alzheimer’s disease (AD), the most common form of demen-
tia in the elderly is defined histologically by the presence of
the two hallmarks: extracellular senile plaques constituted with
amyloid-β (Aβ) proteins and intracellular inclusions of hyper-
phosphorylated microtubule-associated Tau protein, refered as
neurofibrillary tangles (Selkoe, 2004). Clinically, the disease is
characterized by progressive cognitive decline associated with
synaptic and neuronal loss in regions critical for memory pro-
cess, e.g., hippocampus, entorhinal and frontal cortex (Crews
and Masliah, 2010). Mitochondria, which are the main energy
provider in the cell, are particularly enriched in synapses
where energy is critical for synaptic transmission (Verstreken
et al., 2005). Mitochondrial dysfunctions have been consistently
reported as an early event in AD physiopathology and appear
before Aβ deposition and memory deficits in AD patients and
transgenic mice (Maurer et al., 2000; Caspersen et al., 2005;
Mosconi et al., 2008). Indeed, during AD pathogenesis, Aβ
oligomers accumulate in mitochondria, resulting in disrupted
energy metabolism, increased oxidative stress and apoptosis
(Lustbader et al., 2004; Caspersen et al., 2005; Manczak et al.,
2006). Studies in AD patients and transgenic mice have reported
consistent decreases in tricarboxylic acid cycle enzymes and
cytochrome c oxidase activities (Yates et al., 1990; Maurer et al.,
2000; Caspersen et al., 2005; Leuner et al., 2007). Moreover,
studies in isolated mitochondria from transgenic mice brains
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or in isolated mitochondria exposed to Aβ oligomers showed
decreased respiration rates and ATP production and increased
oxidative stress, suggesting Aβ-related defects in mitochondrial
respiratory chain (Casley et al., 2002a; Aleardi et al., 2005;
Caspersen et al., 2005; Clementi et al., 2005; Leuner et al.,
2007). Disruption in mitochondrial respiratory chain results in
increased production of oxidative stress by mitochondria, a key
element in AD physiopathology (Smith et al., 1996; Leuner
et al., 2012). One other aspect of mitochondrial failure is the
opening of mitochondrial permeability transition pore (mPTP)
which can be triggered by different effectors, e.g., mitochon-
drial Ca2+ overload and oxidative stress (Kroemer and Reed,
2000). mPTP opening could also be triggered by the translo-
cation to the mitochondrial outer membrane of the cytosolic
proapototic members of the Bcl-2 family proteins. Among them
is the proapototic protein Bax which, in proapoptotic condi-
tions, translocates to mitochondria, dimerizes and constitutes
a pore in the mitochondrial membrane and/or contributes to
the formation of mPTP (Jürgensmeier et al., 1998; Marzo et al.,
1998; Narita et al., 1998). Bax activity could be antagonized
by heterodimerization with antiapoptotic Bcl-2 family proteins,
including Bcl-2 itself (Hanada et al., 1995; Yin et al., 1995; Yang
et al., 1997). mPTP opening allows liberation of mitochondrial
protein, such as cytochrome c, which promotes apoptosis, binding
to the apoptosis protease activation factor (APAf-1) and forming
a complex indicated as “apoptosome” (Liu et al., 1996; Yang et al.,
1997).
In the present study, we used the intracerebroventricular (ICV)
injection of Aβ25–35 fragment in oligomeric form in mice as
a rapid, standardized pharmacological model of AD toxicity,
suitable to investigate the impact of mitochondrial alteration.
Indeed, ICV Aβ25–35 injection results in neuroinflammation and
reactive gliosis, pro-apoptotic caspase activity, oxidative stress,
reduction in the number of neurons measured in hippocampal
pyramidal cell layers, loss of cholinergic neurons, and memory
deficits (Maurice et al., 1996; Delobette et al., 1997; Meunier
et al., 2006; Villard et al., 2009, 2011; Zussy et al., 2011).
In vitro evidences have been accumulated suggesting that
the peptide also altered mitochondrial physiology, after direct
application on isolated mitochondria or in mitochondria iso-
lated from cultured neurons exposed to Aβ25–35 (Canevari
et al., 1999; Casley et al., 2002a,b; Aleardi et al., 2005;
Clementi et al., 2005; Dong et al., 2010; Ren et al., 2011).
Isolated mitochondria from rat brain subjected to subchronic
ICV injection of Aβ25–35 or Aβ1–40 produced significantly
more H2O2 compared to control mice after three days of
treatment, suggesting mitochondrial dysfunction in this model
(Kaminsky and Kosenko, 2008). However, to our knowl-
edge, the functionality of isolated mitochondria has never
been explored ex vivo after ICV administration of Aβ25–35 in
rodents.
Tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine
hydrochloride (ANAVEX2-73, AE37) is a novel ligand, acting
at muscarinic acetylcholine (mAChR) and σ1 receptors (σ1R)
with affinities in the low micromolar range (Espallergues
et al., 2007). We previously reported that this compound had
anti-amnesic and neuroproective potential in the AD model
in mice induced by the ICV injection of Aβ25–35 peptide. In
particular, ANAVEX2-73 attenuated cellular loss, Aβ1–42 seeding,
Tau hyperphosphorylation and learning and memory deficits
observed several days after Aβ25–35 injection (Villard et al.,
2009, 2011; Lahmy et al., 2013). The drug acts synergistically
on its two main targets, as an antagonist of M2 mAChR and
as an agonist of σ1R. The σ1R is an endoplasmic reticulum
(ER)-resident molecular chaperone (Hayashi and Su, 2007), also
expressed at the mitochondrial membrane (Klouz et al., 2002),
particularly at mitochondria-associated ER membranes (MAM).
Its activity regulates Ca2+ exchange from ER to mitochondria
(Hayashi and Su, 2007), known to be critical for mitochondrial
bioenergetics (Cárdenas et al., 2010). Moreover, the σ1R is
involved in regulation of the mitochondrial membrane potential,
reactive oxygen species (ROS) production and apoptosis (Tsai
et al., 2009; Meunier and Hayashi, 2010) and σ1R agonists have
been shown to protect mitochondrial function in vivo against
ischemic damage (Klouz et al., 2008; Tagashira et al., 2013).
In this study, we analyzed whether the neuroprotective activ-
ity of ANAVEX2-73 involves mitochondrial protection. We ana-
lyzed the respiratory activity in mitochondria isolated from the
mouse hippocampus, five days after ICV injection of oligomer-
ized Aβ25–35. We measured respiration rates of freshly extracted
mitochondria and the activity of the respiratory chain complexes
I to IV. We then analyzed biochemical markers of mitochondrial
damage, including Bax, Bcl-2 protein expression and cytochrome
c release from the mitochondria into the cytosol. PRE-084 was
used as a reference σ1R agonist.
MATERIAL AND METHODS
ANIMALS
Male Swiss OF-1 mice (Depré, St Doulchard, France), aged 7–9
weeks and weighing 32 ± 2 g were used. They were housed
in plastic cages in groups with free access to food and water,
except during behavioral experiments. They were kept in a reg-
ulated environment (23 ± 1◦C, 50–60% humidity) under a
12 h light/dark cycle (light on at 8:00 am). Behavioral exper-
iments were carried out between 10:00 am and 4:00 pm, in
an experimental room within the animal facility. All animal
procedures were conducted in adherence with the 2010/63 EU
Directive.
DRUGS AND ADMINISTRATION PROCEDURES
The amyloid-β[25–35] (Aβ25–35) and scrambled Aβ25–35 (Sc. Aβ)
peptides were purchased from Genepep (Saint Jean-de-Védas,
France). They were solubilized in sterile distilled water at a
concentration of 3 mg/ml and stored at −20◦C until use.
Before injection, peptides were aggregated by incubation at
37◦C for 4 days (Maurice et al., 1996). This procedure is
currently standardized in the laboratory and previous analyses
using electronic microscopy, IR spectroscopy, and photon
correlation spectroscopy techniques showed that the aggregated
Aβ25–35 solution is mainly composed of a mixture of soluble
oligomeric amyloid species, which sizes extended from 52.8
to 295.3 nm (98%) (Zussy et al., 2011, 2013). They were
administered intracerebroventricularly (ICV) in a final volume
of 3 µl per mouse, as previously described (Maurice et al., 1996;
Frontiers in Cellular Neuroscience www.frontiersin.org January 2015 | Volume 8 | Article 463 | 2
Lahmy et al. Mitochondrial protection by ANAVEX2-73 in Alzheimer’s disease
Meunier et al., 2006). Tetrahydro-N,N-dimethyl-2,2-diphenyl-
3-furanmethanamine hydrochloride (ANAVEX2-73, AE37) was
provided by Dr Alexandre Vamvakides (Anavex Life Science,
Pallini, Greece). PRE-084 was a gift from Dr Tsung-Ping Su
(NIDA/NIH, Baltimore, MD, USA). 2-(3,4-Dichlorophenyl)-N-
(2-dimethylaminoethyl)-N-methylethanamine dihydrobromide
(BD1047) was from Sigma-Aldrich (St Quentin-Fallavier,
France). Drugs were solubilized in physiological saline at the
concentration of 5 mg/ml and then diluted to the appropriate
concentrations. They were injected intraperitoneally (IP) in a vol-
ume of 100µl/20 g body weight. Drugs were injected once, 20 min
before the Aβ25–35 peptide, also injected once. Animals were used
1, 3, 5, or 7 days after injections, as indicated in the figure legends.
LIPID PEROXIDATION
Mice were killed by decapitation and brains were rapidly removed,
the hippocampus dissected out, weighed, and kept in liquid nitro-
gen until assayed. After thawing, the hippocampus was homog-
enized in cold methanol (1/10 w/v), centrifuged at 1,000 g for
5 min and the supernatant collected. Homogenate was added
to a solution containing 1 mM FeSO4, 0.25 M H2SO4, 1 mM
xylenol orange, and incubated for 30 min at room temperature.
Absorbance was measured at 580 nm (A5801), and 10 ml of
1 mM cumene hydroperoxide (CHP; Sigma-Aldrich) was added
to the sample and incubated for 30 min at room temperature, to
determine the maximal oxidation level. Absorbance was measured
at 580 nm (A5802). The level of lipid peroxidation was deter-
mined as CHP equivalents according to: CHP eq. 1/4 A5801/A5802
[CHP (nmol)] dilution, and expressed as CHP eq. per wet tissue
weight.
RESPIRATION RATES
Five days after peptide injection, mice were sacrificed, and
their hippocampus rapidly removed on ice and homogenized
in 10 ml of ice-cold homogenization buffer (220 mM man-
nitol, 70 mM sucrose, 10 mM 2-[4-(2-hydroxyethyl)piperazin-
1-yl]ethanesulfonic acid (HEPES; Sigma-Aldrich), 2 mM ethylene
glycol tetraacetic acid (EGTA; Sigma-Aldrich), pH 7.4) using
a Teflon potter homogenizer. Homogenate was centrifuged at
1,000 g for 5 min. The supernatant was then centrifuged at
10,000 g for 10 min. Pellet was collected and resuspended in 50 µl
of ice-cold isolation buffer (220 mM mannitol, 70 mM sucrose,
10 mM HEPES, 0.01 mM EGTA, pH 7.4). Mitochondrial protein
content was determined by spectrophotometry. O2 consumption
was measured with a Clarke type oxygen electrode (Hansatech,
Cergy, France). Mitochondria (0.8 mg/ml) were loaded in the
chamber filled up with respiration buffer maintained at 30◦C
(50 mM sucrose, 100 mM KCl, 10 mM HEPES, 5 mM KH2PO4,
0.5 mM MgCl2, pH 7.4). State 2 respiration was measured after
addition of 5 mM pyruvate-malate and state 3 respiration was
triggered by addition of 0.5 mM adenosine diphosphate (ADP;
Sigma-Aldrich). State 4 respiration was then measured after
addition of 4 µM carboxyatractyloside (CAT; Sigma-Aldrich),
a blocker of the adenosine trisphosphate (ATP)-ADP car-
rier, and uncoupled state with 1 µM tyrphostine (uncoupling
agent). The mean of two measures of respiration rates for
the four states were calculated for each sample. The control
ratio was calculated as the ratio between state 3 and state 4
respiratory rates.
In a series of experiment, the effects of direct application of
the drugs (ANAVEX2-73 and PRE-084, in the 10−8 to 10−4 M
concentration range) were examined. Isolated mitochondria
(0.8 mg/ml) were loaded in the chamber. Drugs were applied and
after 5 min, the respiration was examined.
COMPLEX ACTIVITIES
Five days after peptide injection, mice were sacrificed, and their
hippocampus rapidly removed on ice. Mitochondria were isolated
in the same way as for respiration rates. Mitochondrial protein
content was determined using a BCA assay (Pierce Biotechnol-
ogy, Rockford, IL, USA). Mitochondria were frozen/thawed four
times to break mitochondrial membranes. Complex activities
were measured at 30◦C, using a Jasco V-530 spectrophotome-
ter (Jasco, Nantes, France). Complex activities are calculated as
nmol/min/mg of proteins and expressed as percentage of Sc.
Aβ-treated group data.
Complex I (NADH ubiquinone reductase)
The oxidation of nicotinamide adenine dinucleotide (NADH;
Sigma-Aldrich) by complex I was measured using decylu-
biquinone (DUQ; Sigma-Aldrich), an ubiquinone analog, as elec-
tron acceptor. 200 µM NADH and 100 µM DUQ were added
to the assay medium (25 mM KH2PO4, 5 mM MgCl2, 250 µM
KCN, 1 mg/ml bovine serum albumin (BSA; Sigma-Aldrich),
pH 7.4) in a final volume of 1.5 ml. Enzyme activity was
measured by initiating the reaction with 0.15 mg of mitochondrial
protein. The decrease in absorbance due to NADH oxidation was
measured at 340 nm.
Complex II (succinate dehydrogenase)
The activity of complex II was measured indirectly by record of
the reduction of 2,6-dichlorophenolindo-phenol (DCIP; Sigma-
Aldrich) following the oxidation of succinate. 6 mM succinate
was incubated with 0.05 mg of mitochondrial proteins for 5 min
at 30◦C in the assay medium (10 mM KH2PO4, 2 mM ethylene-
diaminetetraacetic acid (EDTA; Sigma-Aldrich), 2 µM rotenone,
1 mg/ml BSA) in a final volume of 1.5 ml. 100 µM DUQ and
80 µM DCIP were then added and the decrease in absorbance
at 600 nm, corresponding to the reduction of DCIP, was
measured.
Complex III (ubiquinol cytochrome c reductase)
The oxidation of DUQH2 by complex III was determined using
cytochrome c(III) as an electron acceptor. 0.25 mg of mito-
chondrial protein was added in the assay medium (10 mM
KH2PO4, 2 mM EDTA, 1 mg/ml BSA, 2 µM rotenone, 250
µM KCN) in a final volume of 1.5 ml. The reaction was
started with the addition of 100 µM DUQH2 (Sigma-Aldrich)
and the increase in absorbance at 550 nm, corresponding to
reduction of cytochrome c was measured. Because cytochrome
c(III) could also be reduced by DUQH2 independently of com-
plex III, the reduction of cytochrome c(III) was measured in
the presence of 1 µM antimycin (an inhibitor of complex
III activity) and deducted from the total reduction measured
before.
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Complex IV (cytochrome c oxidase)
0.025 mg of mitochondrial protein were incubated for 1 min at
30◦C in the assay medium (10 mM KH2PO4, 10 mM EDTA,
2 mM MgCl2, 1 mg/ml BSA) in a final volume of 1.5 ml.
The reaction was started when 33 µM of cytochrome c(II) was
added to the assay medium and the decreased in absorbance at
550 nm, corresponding to oxidation of cytochrome c(II), was
measured.
WESTERN BLOTTING
Mice were sacrificed at indicated days after injections and the
hippocampus rapidly dissected on ice and kept at −80◦C until
used. For cytochrome c release experiments, the hippocampus
were homogenized with a glass Dounce homogenizer in ice-
cold homogenization buffer (250 µM sucrose, 10 mM HEPES,
pH 7.4), including a protease and phosphatase inhibitor cock-
tail (Roche Diagnostics, Meylan, France) in a final volume of
250 µl. Homogenates were centrifuged at 600 g for 5 min and
the supernatant collected and centrifuged again at 10,300 g
for 20 min. The supernatant, corresponding to the cytoso-
lic fraction (C), and the pellet, corresponding to the crude
mitochondrial fraction (M), were separated. The mitochon-
drial fraction was resuspended in 50 µl of ice-cold isolation
buffer (250 mM mannitol, 5 mM HEPES, 0.5 mM EGTA,
pH 7.4).
For Bax and Bcl-2 experiments, the hippocampus were
homogenized by sonication in an ice-cold lysis buffer (125
mM Tris HCl pH 6.8, 4% sodium dodecyl sulfate (SDS;
Sigma-Aldrich), 20% glycerol) including a protease and phos-
phatase inhibitor cocktail (Roche Diagnostics, Meylan, France).
Homogenates were heated at 70◦C for 10 min and centrifuged at
16,000 g for 30 min. The supernatant was collected.
For all samples, protein concentration was determined using a
BCA assay (Pierce Biotechnology, Rockford, IL, USA) according
to the manufacturer’s instructions.
Proteins, 20 µg per lane, were resolved on a 12% SDS-
polyacrylamid gel and transfered to a polyvinylidene flu-
oride (PVDF) membrane (GE Healthcare, Orsay, France).
After 1 h blocking in 5% non-fat dry milk in a 20
mM Tris-buffered saline pH 7.5 buffer containing 0.1%
Tween-20 (TBS-T), membranes were incubated overnight at
4◦C with the following primary antibodies: mouse anti-
cytochrome c (CytC, dilution 1/1000; BioLegend, San Diego,
CA, USA), mouse anti-oxphos-complex IV subunit I (Oxphos,
1/1000; Invitrogen Life Technologies, St Aubin, France), rab-
bit anti-Bax (1/2000; Cell Signaling Technology, Ozyme,
St Quentin-en-Yvelines, France), mouse anti-Bcl-2 antibody
(1/1000; Santa Cruz Biotechnology; Heidelberg, Germany).
After brief washes, membranes were incubated for 1 h at
room temperature with corresponding secondary antibody:
goat anti-mouse IgG peroxidase conjugate (1/2000; Sigma-
Aldrich) or goat anti-rabbit IgG peroxidase conjugate (1/2000;
Sigma-Aldrich). The immunoreactive bands were visualized
with the enhanced chemiluminescence reagent (ECL, Milli-
pore, Molsheim, France) using an Odysseyr Fc fluorescent
imaging system (Li-Cor, Eurobio, Courtaboeuf, France). Then,
membranes were stripped using the Restore Western Blot
Stripping Buffer (Pierce Biotechnology) and reprobed with anti-
β-tubulin antibody (1/2000) (Sigma-Aldrich). The intensity of
peroxidase activity was quantified using the Odysseyr Fc software
(Li-Cor).
STATISTICAL ANALYSES
Data were expressed as mean ± S.E.M. The number of animals is
indicated in the figure legends. Data were analyzed using one-way
ANOVA (F values), followed by the Dunnett’s post-hoc multiple
comparison test. For reading clarity, ANOVA values were all
reported in the figure legends. The level of statistical significance
was p< 0.05.
RESULTS
ICV administration of Aβ25–35 in mice induced a robust
(+50–70%) increase in lipid peroxidation level in the hip-
pocampus of the animals, starting at 5–7 days after injection
(Figure 1A). The IP pretreatment with ANAVEX2-73, in the
0.01–1 mg/kg dose-range dose-dependently prevented the
Aβ25–35-induced increase in lipid peroxidation with highly sig-
nificant effect measured at 0.3 and 1 mg/kg (Figure 1B).
The reference σ1R agonist PRE-084 similarly blocked Aβ25–35-
induced increase in lipid peroxidation at 0.5 and 1 mg/kg
(Figure 1C). Note that both drug effects at the highest doses
were completely blocked by the reference σ1R antagonist BD1047,
confirming the σ1R selectivity (Figures 1B,C). These initial
observations confirmed that ICV injection of Aβ25–35 induces a
marked oxidative stress in mice and that the two compounds
act as anti-oxidant drugs. The prominent role of mitochondrial
dysfunction in ROS generation and oxidative stress led us to
analyze the impact of the drug treatments on mitochondrial
respiration.
O2 consumption was analyzed in mice, five days after Sc.
Aβ and Aβ25–35 injection, and following ANAVEX2-73 or PRE-
084 treatment (Figure 2). The Aβ25–35 ICV treatment failed
to affect state 2 or state 4 O2 consumption (Figure 2A), but
significantly altered by−23% and−22% the state 3 or uncoupled
state O2 consumption, respectively (Figure 2B). As a conse-
quence the peptide injection significantly altered the respira-
tory control ratio by −17% (Figure 2C). The ANAVEX2-73
treatment (0.3 mg/kg IP) significantly prevented the Aβ25–35-
induced decreases in O2 consumption (Figure 2B). However,
since the drug increased in fact significantly O2 consump-
tion at all states (Figure 2A), there was no significant impact
on the respiratory control ratio (Figure 2C). A similar pro-
file was observed with PRE-084 (0.5 mg/kg IP) in Aβ25–35-
treated mice (Figures 2A,B) but the increase in state 3 O2
consumption was more marked resulting in a restoration of
the respiratory control ratio value, i.e., a significant preven-
tion of the Aβ25–35-induced alteration (Figure 2C). Note that
neither ANAVEX2-73 nor PRE-084 affected O2 consumption
in Sc. Aβ-treated animals. In addition, we analyzed whether
the drugs have a direct effect on mitochondrial respiration.
The drugs were both applied at increasing concentrations,
from 10−8 M to 10−4 M, on isolated mitochondria and
respiration analyzed. State 3 O2 consumption and respira-
tory control ratio are presented (Figures 3A,B). The drugs
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FIGURE 1 | ANAVEX2-73 and PRE-084 prevented oxidative stress in
Aβ25–35-treated mice. Mice were administered ICV with Sc. Aβ or Aβ25–35
peptide (9 nmol) and sacrificed after 1, 3, 5 or 7 days for lipid peroxidation
measures (A). n = 6 per group, ∗p < 0.05, ∗∗∗p < 0.001 vs. the (Sc. Aβ +
V)-treated group at the same timepoint; t-test. Mice were then administered
IP with (B) ANAVEX2-73 (0.01–1 mg/kg) or (C) PRE-084 (0.5–1 mg/kg) 20 min
before Aβ25–35 (9 nmol). In two groups, BD1047 (10 mg/kg) was administered
simultaneously with the highest dose of each agonist. Mice were sacrificed
after 7 days for lipid peroxidation measures. One-way ANOVA: F (7,70) = 22.5, p
< 0.0001, n = 6–14 per group in (B); F (4,69) = 31.9, p < 0.0001, n = 6–22 in
(C). ∗∗p < 0.01, ∗∗∗p < 0.001 vs. the (Sc. Aβ+V)-treated group; ###p < 0.001
vs. the (Aβ25–35+V)-treated group; Dunnett’s test.
affected both parameters only at the highest concentrations
tested.
We analyzed the nature of the Aβ25–35-induced alteration
of respiration (Figure 4). The measure of each complex activ-
ity showed that only the complex IV activity was significantly
decreased by −14% (Figure 4A). The ANAVEX2-73 treatment
prevented the Aβ25–35-induced decrease in complex IV activity
(Figure 4B).
Among the different biochemical markers that can be exam-
ined to evidence the damage resulting from impaired mito-
chondrial functionality, we first addressed cytochrome c release
from the mitochondrial membrane into the cytosol (Figure 5A).
The time-course analysis showed that significant cytochrome c
release can be evidenced at day 5 after the peptide injection
(Figure 5B). At this timepoint, both the ANAVEX2-73 treatment
(Figure 5C) and PRE-084 treatment (Figure 5D) completely
prevented the Aβ25–35-induced cytochrome c release in the mouse
hippocampus.
We then measured Bax and Bcl-2 protein expression, by a
western blot approach, in order to confirm that the impact of
the treatment on mitochondrial damage readily transfer into anti-
apoptosis protection (Figure 6). The Aβ25–35 treatment resulted,
between 1 to 7 days after injection, in a progressive but non-
significant increase in Bax level in the hippocampus (Figure 6A),
accompanied by a trend to diminution of Bcl-2 level (Figure 6B).
As a consequence, the Bax/Bcl-2 ratio increased, and significantly
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FIGURE 2 | ANAVEX2-73 (AN2-73) and PRE-084 (PRE) protected against
Aβ25–35-induced alteration of mitochondrial respiration in mice. Mice
were treated with ANAVEX2-73 (0.3 mg/kg IP), PRE-084 (0.5 mg/kg IP) or
vehicle, before injection of Sc. Aβ or Aβ25–35 (9 nmol ICV). (A–C) Mitochondria
(0.8 mg/ml) were loaded in the chamber with appropriate buffer at 30◦C.
State 2 respiration was activated by addition of pyruvate-malate
(5 mM). State 3 respiration was induced with ADP. State 4 respiration was
provoked by the addition of carboxyatractyloside (CAT), a blocker of ATP-ADP
carrier. Finally, addition of tyrphostine, an uncoupling agent, activated the
uncoupled respiration. The respiratory control ratio is the state 3/state 4 ratio.
n = 4–8 per group, F (5,38) = 7.11, p < 0.0001 for state 2 and F (5,38) = 8.43,
p < 0.0001 for state 4 in (A); F (5,38) = 13.1, p < 0.0001 for state 3 and F (5,38)=
8.43, p < 0.0001 for state 3 in (B); F (5,38) = 2.58, p < 0.05 in (C). ∗p < 0.05,
∗∗p < 0.01 vs. Sc. Aβ/Veh; #p < 0.05, ##p < 0.01, ###p < 0.001 vs.
Aβ25–35/Veh. Dunnett’s test. (D) Typical trace of O2 consumption for Sc. Aβ
and Aβ25–35-injected mice.
FIGURE 3 | Direct application of ANAVEX2-73 or PRE-084 affected
mitochondrial respiration only at high concentrations. Mitochondria
(0.8 mg/ml) were loaded in the chamber with appropriate buffer at 30◦C.
The drugs (10−8 to 10−4 M) were bath applied 5 min before the repspiration
measures. State 2 respiration was activated by addition of pyruvate-malate
(5 mM). State 3 respiration was induced with ADP. State 4 respiration was
provoked by the addition of carboxyatractyloside (CAT), a blocker of ATP-ADP
carrier. The respiratory control ratio is the state 3/state 4 ratio. n = 4–8 per
group (n = 14 for the no-drug group), F (5,38) = 3.08, p < 0.05 for ANAVEX2-73
and F (5,31) = 5.19, p < 0.01 for PRE-084 in (A); F (5,38) = 22.1, p < 0.0001 for
ANAVEX2-73 and F (5,31)= 7.53, p < 0.001 for PRE-084 in (B). ∗p < 0.05,
∗∗p < 0.01, ∗∗∗p < 0.001 vs. no-drug data; Dunnett’s test.
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FIGURE 4 | ANAVEX2-73 protected against Aβ25–35-induced alteration
of complex IV activity. Mitochondria were loaded in the
spectrophotometer cuvette with appropriate buffer at 30◦C and variations of
absorption were recorded after addition of specific substrates. (A) Effect of
Aβ25–35 ICV injection on complex activities (% of Sc. Aβ) n = 8–9 per group,
* p < 0.05 vs. Sc. Aβ Student’s t-test. (B) Mice were treated with
ANAVEX2-73 (0.3 mg/kg IP) or vehicle, before injection of Sc. Aβ or Aβ25–35
(9 nmol ICV). Complex IV activity was measured after 7 days (% of Sc. Aβ).
n = 5–9 per group, F (3,26) = 3.00, p < 0.05. * p < 0.05 vs. Sc. Aβ; Dunnett’s
test.
at days 5 and 7 after the peptide injection (Figure 5C). ANAVEX2-
73 was tested at 0.1–1 mg/kg. A dose-dependent decrease in
Bax level was measured at the highest dose tested (Figure 6D).
The drug impacted marginally Bcl-2 levels (Figure 6E), but the
data examined as Bax/Bcl-2 ratio clearly showed a beneficial
effect of the compound, particularly significant at 0.3 mg/kg
(Figure 6F).
DISCUSSION
In this study, we showed that mitochondrial functionality was
altered several days after an ICV injection of the Aβ25–35 peptide
in mouse. It was shown by reduced respiration rates, decreased
complex IV activity and increased oxidative stress and proapop-
totic markers. Five days after a single injection of oligomeric
Aβ25–35 peptide, respiration was reduced in isolated mitochon-
dria from mouse hippocampus, as compared with control Sc.
Aβ-treated mice. Basal respiration (State 2 and State 4) was
unaffected by Aβ25–35, but ADP-stimulated respiration (State 3)
was significantly decreased. Reduced State 3 respiration resulted
in a decreased control ratio in Aβ25–35-injected mice. Uncoupled
state was also altered, suggesting a defect in respiratory chain
complex I-IV rather than a defect in ATP synthase complex
activity. The reduced respiratory rates and control ratio observed
in this in vivo model are coherent with previous studies explor-
ing the impact of Aβ peptides, and particularly Aβ25–35, on
mitochondrial respiration in vitro. Application of Aβ25–35 on
isolated mitochondria decreased respiration rates (Casley et al.,
2002a; Aleardi et al., 2005; Clementi et al., 2005). Interestingly,
in these studies, basal respiration (State 4) was also altered
after Aβ25–35 treatment. In the same way, mitochondria iso-
lated from cultured neurons and exposed to Aβ25–35 showed
decreased ATP production, suggesting a reduced mitochondrial
respiration (Casley et al., 2002b; Dong et al., 2010). In search
for an explanation to this decreased mitochondrial respira-
tion after Aβ25–35, we measured the respiratory chain complex
I-IV activities. We found that complex IV activity was signif-
icantly reduced 5 days after Aβ25–35. In most of the in vitro
studies, application of Aβ25–35 on cultured neurons or directly on
isolated mitochondria resulted in reduced activities of complexes
I and IV (Casley et al., 2002a,b; Aleardi et al., 2005; Clementi
et al., 2005; Dong et al., 2010). This appears to be a difference
between in vitro and in vivo studies with the Aβ25–35 pep-
tide. It could explain the decreased state 4 respiration observed
in vitro. But, consistent with our results, are data in trans-
genic mice expressing human mutant amyloid precursor protein
(hAPPm). Aβ peptide has been found to accumulate in
mitochondria and respiratory rates and complex IV activity
were also decreased in these animals (Caspersen et al., 2005;
Rhein et al., 2009; Du et al., 2010). Moreover, Canevari et al.
(1999) described a specific and concentration-dependent decrease
in complex IV activity after Aβ25–35 application in isolated
mitochondria. Disruption of complex IV activity induced by
Aβ peptides could be due to a direct interaction between Aβ
and the enzymatic subunits (Crouch et al., 2006; Hernandez-
Zimbron et al., 2012) but also to the direct induction of oxida-
tive stress by Aβ peptides, and particularly Aβ25–35. Indeed,
membrane lipid peroxidation induced by ROS overproduction
might alter complex IV subunits and disrupt complex IV activity
(Paradies et al., 1998; Bobba et al., 2013), as we confirmed
the marked increase in oxidative stress in mouse hippocampus,
already described in this model (Meunier et al., 2006). The
release of cytochrome c from mitochondria into the cytosol that
was increased 5 days after Aβ25–35 injection can also contribute
to the dysfunction of the mitochondrial respiratory chain and
thus to the oxidative stress. Concomitantly to the cytochrome c
release, the ratio Bax/Bcl-2 was significantly increased in mouse
hippocampus, 5 and 7 days after Aβ25–35 injection and this is
likely related to the cellular response to the high level of oxidative
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FIGURE 5 | ANAVEX2-73 and PRE-084 prevented Aβ25–35-induced
cytochrome c release. (A) Typical blots of mitochondrial (M) and cytosolic (C)
fractions with cytochrome c, oxphos and β-tubulin antibodies. (B) Cytochrome
c content (cytosol to mitochondrial content ratios). Mice were injected with
Sc. Aβ or Aβ25–35 (9 nmol ICV) and sacrificed at indicated days. n = 9–12 per
group. * p < 0.05 vs. Sc. Aβ. Student’s t-test. (C, D) Mice were treated with
ANAVEX2-73 (0.3 mg/kg IP) or PRE-084 (0.5 mg/kg IP) before Aβ25–35 and
sacrificed after 5 days. n = 8–17, F (2,37) = 5.96, p < 0.01 in (C); n = 8–14,
F (2,33) = 8.19, p < 0.01 in (D). ∗p < 0.05, ∗∗p < 0.01 vs. Sc. Aβ, #p < 0.05, ##p
< 0.01 vs. Aβ25–35; Dunnett’s test.
stress and decreased mitochondrial respiration (Mattson et al.,
2008).
The aim of the study was to establish whether the localization
of the σ1R on mitochondria (Klouz et al., 2002) and more
precisely at MAM (Hayashi and Su, 2007) is related to its
particular neuroprotective activity. Indeed, both ANAVEX2-73
and PRE-084, prevented Aβ25–35-induced oxidative stress and
increase in pro-apototic markers. The results are coherent with
previously reported observations, since the σ1R has been involved
in regulation of oxidative stress (Pal et al., 2012; Tsai et al.,
2012). Moreover, σ1R agonists prevented oxidative stress-induced
apoptosis in vitro through upregulation of the anti-apoptotic
Bcl-2 protein expression (Meunier and Hayashi, 2010).
The σ1R activation also prevented Bax increase and caspase-
3 activation, linked to cytochrome c release, after glutamate
insult in retinal ganglional cells (Tchedre and Yorio, 2008).
Another study also showed a decreased caspase-3 activation
after PRE-084 treatment in a Huntington’s disease model
(Hyrskyluoto et al., 2013). ANAVEX2-73 and PRE-084 both
fully reversed state 3 and uncoupled state respiration deficits.
Surprisingly both drugs also increased basal respiration (state
2 and state 4) and PRE-084, but not ANAVEX2-73 increased
state 3 and uncoupled state respiration, compared to control
mice. These differences in ANAVEX2-73 and PRE-084 effects
could be explained by the higher affinity of the later for the
σ1 receptor. Although state 3 respiration raised to the control
level after ANAVEX2-73 treatment, CR was not different from
the Aβ25–35 group because state 4 respiration also increased.
However, the high increased of both state 3 and state 4 respiration
after PRE-084 treatment increased the control ratio to the
control level. Such increased respiration after stimulation
of σ1R has never been described and is not observed in Sc.
Aβ-treated control mice. An attempt to explain this phenomenon
is challenging. The increased state 3 and uncoupled state
respiration rates observed after PRE-084 treatment were
clearly not an artifact or due to experimental conditions as
all the samples were prepared in strictly the same way and
measures realized randomly among treatment groups and in
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several experimental sessions. Few studies have examined the
involvement of σ1R in mitochondrial respiration. BHDP is a
selective ligand with nanomolar affinity for the σ1 receptor
(Klouz et al., 2003). A three days pretreatment with BHDP
in rats prevented the decrease in CR in mitochondria isolated
from rat liver after ischemia-reperfusion (Klouz et al., 2008).
We previously suggested that protective effect on mitochondrial
function of σ1 agonist could be attributable to the presence
of σ1R to the mitochondrial membrane (Klouz et al., 2002).
Indeed, σ1R are present in lipid rafts and modify their
composition and particularly the ganglioside content (Hayashi
and Su, 2005). In mitochondrial membrane, lipid rafts
microdomains, and particularly the glycosphingolipid GD3,
are involved in alteration of mitochondrial membrane potential
and apoptosis (Malorni et al., 2007). Therefore, an explanation
of increased mitochondrial respiration by σ1 ligand could be
through the capacity of the protein to modulate lipid rafts
gangliosids at mitochondrial membrane. Another explanation
could be the chaperone activity of the σ1 protein on InsP3
receptor at the ER membrane (Hayashi and Su, 2007). The InsP3
receptor stabilization allows proper Ca2+ exchange between
ER and mitochondria, which are critical for mitochondrial
bioenergetics (Cárdenas et al., 2010). Cutamesine (SA4503),
another selective σ1 agonist, increased ATP production
in cardiomyocytes, even without pathological conditions,
suggesting an increase in mitochondrial respiration after σ1R
stimulation (Tagashira et al., 2013). The increased mitochondrial
bioenergetics after σ1 agonist treatment is largely attribuable to
ER Ca2+ mobilization into mitochondria, because treatment with
xestospongin C, an antagonist of the InsP3 receptor abolished
the effects of the σ1 agonist on ATP production. However, in
our model, this mechanism did not seem to be involved in
the σ1 protein-induced increased mitochondrial respiration
because the agonist was injected only once, five days before the
mitochondrial isolation. Moreover, Tsai et al. (2009) described
Ca2+-independent perturbations of mitochondrial functions in
hippocampal neurons after σ1 receptor knockdown with siRNA.
To note, another interesting consequence of σ1R activity is the
modulation of different genes expression. Some of them are
involved in oxidative stress regulation, e.g., NAD(P)H quinone
oxidoreductase (Nqo1), Superoxide dismutase (SOD), Atf-4
and Prdx6 (Pal et al., 2012; Tsai et al., 2012). It could be worth
investigating whether the PRE-084-induced increased respiratory
efficacy could be due to the modification of expression of specific
genes.
In conclusion, we provided here the clear evidence that the
neuroprotective activity of σ1 receptor agonists, including the
mixed muscarinic ligand/σ1 agonist ANAVEX2-73, involves mito-
chondrial protection in AD models. Indeed, the drug protected
mitochondria against Aβ25–35 insult. Mitochondrial dysfunction
in AD is a critical hallmark of the pathology, as mitochon-
dria are, at the same time, a target and promoter of the phys-
iopathological processus (for review, see Eckert et al., 2010;
Selfridge et al., 2013). Mitochondrial dysfunction and, notably,
resulting oxidative stress are responsible for the increased Aβ
production (Dyrks et al., 1992; Leuner et al., 2007) and Tau
hyperphosphorylation (Melov et al., 2007), the two biochemical
FIGURE 6 | ANAVEX2-73 protected against Aβ25–35-induced increase in
Bax/Bcl-2 ratio in the mouse hippocampus. (A–C) Mice were sacrificed
at 1, 3, 5 and 7 days after Aβ25–35 injection and Bax and Bcl-2 contents
determined by western blots. (D–F) Effect of ANAVEX2-73 (0.1–1 mg/kg IP)
on Bax and Bcl-2 levels, 7 days after Aβ25–35 injection. Typical blots are
represented above the bar graphs. Mice were injected with ANAVEX2-73 or
vehicle before Aβ25–35 peptide (9 nmol). n = 5–15 per groups. F (4,44) = 1.98,
p > 0.05 in (A) ; F (4,44) = 1.95, p > 0.05 in (B) ; F (4,44) = 2.66, p < 0.05 in
(C); F (4,49)= 3.01, p < 0.05 in (D), F (4,49) = 0.89, p > 0.05 in (E), F (4,49) =
3.09, p < 0.05 in (F). ∗p < 0.05, ∗∗p < 0.01 vs. Sc. Aβ; #p < 0.05 vs.
Aβ25–35; Dunnett’s test.
signatures of AD. Thus, by preserving mitochondrial function
ANAVEX2-73 could expectedly be more than a symptomatic
drug and block the physiopathological amplification of the
pathology.
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